Literature DB >> 15298029

Infectious titer assay for adeno-associated virus vectors with sensitivity sufficient to detect single infectious events.

Zhu Zen1, Yero Espinoza, Thieu Bleu, Jürg M Sommer, J Fraser Wright.   

Abstract

A highly sensitive assay for determination of infectious titers of recombinant adeno-associated virus (AAV) by limiting dilution analysis is described. This assay is capable of detecting single infectious events and can therefore provide an absolute rather than relative measure of infectivity. The assay utilizes a HeLa-derived AAV2 Rep/Cap-expressing cell line, D7-4, grown in 96-well plates and infected with replicate 10-fold serial dilutions of AAV2 vectors in the presence of adenovirus type 5. Forty-eight hours after infection, vector genome replication is determined by quantitative PCR (Q-PCR). A linear relationship between vector genome input and replicated copy number (slope = 2670 copies per vector genome) was determined, enabling detection of one infectious event per well by Q-PCR. The observed binomial distribution of the end-point data confirmed that single infectious events could be detected, and allowed calculation of infectious titers by the Kärber method. Analysis of an AAV2 reference vector, AAV-hFIX16, in 21 independent determinations gave an average ratio of AAV vector genomes (VG) to infectious units (IU) of 8.3 +/- 4.2 VG/IU, a value close to the theoretical limit. No significant differences in vector particle-to-infectious unit ratios were observed between vectors purified by column chromatography (9.3 +/- 5.0 VG/IU, n = 7) and cesium chloride gradient ultracentrifugation (6.4 +/- 3.2 VG/IU, n = 7).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15298029     DOI: 10.1089/1043034041361262

Source DB:  PubMed          Journal:  Hum Gene Ther        ISSN: 1043-0342            Impact factor:   5.695


  15 in total

1.  Virus-delivered small RNA silencing sustains strength in amyotrophic lateral sclerosis.

Authors:  Timothy M Miller; Brian K Kaspar; Geert J Kops; Koji Yamanaka; Lindsey J Christian; Fred H Gage; Don W Cleveland
Journal:  Ann Neurol       Date:  2005-05       Impact factor: 10.422

2.  Quantification of Adeno-Associated Virus with Safe Nucleic Acid Dyes.

Authors:  Jian Xu; Steven H DeVries; Yongling Zhu
Journal:  Hum Gene Ther       Date:  2020-07-14       Impact factor: 5.695

3.  Characterization of a recombinant adeno-associated virus type 2 Reference Standard Material.

Authors:  Martin Lock; Susan McGorray; Alberto Auricchio; Eduard Ayuso; E Jeffrey Beecham; Véronique Blouin-Tavel; Fatima Bosch; Mahuya Bose; Barry J Byrne; Tina Caton; John A Chiorini; Abdelwahed Chtarto; K Reed Clark; Thomas Conlon; Christophe Darmon; Monica Doria; Anne Douar; Terence R Flotte; Joyce D Francis; Achille Francois; Mauro Giacca; Michael T Korn; Irina Korytov; Xavier Leon; Barbara Leuchs; Gabriele Lux; Catherine Melas; Hiroaki Mizukami; Philippe Moullier; Marcus Müller; Keiya Ozawa; Tina Philipsberg; Karine Poulard; Christina Raupp; Christel Rivière; Sigrid D Roosendaal; R Jude Samulski; Steven M Soltys; Richard Surosky; Liliane Tenenbaum; Darby L Thomas; Bart van Montfort; Gabor Veres; J Fraser Wright; Yili Xu; Olga Zelenaia; Lorena Zentilin; Richard O Snyder
Journal:  Hum Gene Ther       Date:  2010-10       Impact factor: 5.695

4.  AAV2 production with optimized N/P ratio and PEI-mediated transfection results in low toxicity and high titer for in vitro and in vivo applications.

Authors:  Xinping Huang; Antja-Voy Hartley; Yishi Yin; Jeremy H Herskowitz; James J Lah; Kerry J Ressler
Journal:  J Virol Methods       Date:  2013-06-19       Impact factor: 2.014

5.  AAV2-mediated gene delivery to monkey putamen: evaluation of an infusion device and delivery parameters.

Authors:  Laura M Sanftner; Jurg M Sommer; Brian M Suzuki; Peter H Smith; Sharmila Vijay; Joseph A Vargas; John R Forsayeth; Janet Cunningham; Krys S Bankiewicz; Haihwa Kao; Jan Bernal; Glenn F Pierce; Kirk W Johnson
Journal:  Exp Neurol       Date:  2005-08       Impact factor: 5.330

6.  Long-term safety and efficacy following systemic administration of a self-complementary AAV vector encoding human FIX pseudotyped with serotype 5 and 8 capsid proteins.

Authors:  Amit C Nathwani; Cecilia Rosales; Jenny McIntosh; Ghasem Rastegarlari; Devhrut Nathwani; Deepak Raj; Sushmita Nawathe; Simon N Waddington; Roderick Bronson; Scott Jackson; Robert E Donahue; Katherine A High; Federico Mingozzi; Catherine Y C Ng; Junfang Zhou; Yunyu Spence; M Beth McCarville; Marc Valentine; James Allay; John Coleman; Susan Sleep; John T Gray; Arthur W Nienhuis; Andrew M Davidoff
Journal:  Mol Ther       Date:  2011-01-18       Impact factor: 11.454

7.  Bioengineered AAV Capsids with Combined High Human Liver Transduction In Vivo and Unique Humoral Seroreactivity.

Authors:  Nicole K Paulk; Katja Pekrun; Erhua Zhu; Sean Nygaard; Bin Li; Jianpeng Xu; Kirk Chu; Christian Leborgne; Allison P Dane; Annelise Haft; Yue Zhang; Feijie Zhang; Chris Morton; Marcus B Valentine; Andrew M Davidoff; Amit C Nathwani; Federico Mingozzi; Markus Grompe; Ian E Alexander; Leszek Lisowski; Mark A Kay
Journal:  Mol Ther       Date:  2017-09-25       Impact factor: 11.454

8.  Analysis of recombinant adeno-associated viral vector shedding in sheep following intracoronary delivery.

Authors:  Melad Farraha; Michael A Barry; Juntang Lu; Jim Pouliopoulos; Thi Y L Le; Sindhu Igoor; Renuka Rao; Cindy Kok; James Chong; Eddy Kizana
Journal:  Gene Ther       Date:  2019-08-29       Impact factor: 5.250

9.  Near-perfect infectivity of wild-type AAV as benchmark for infectivity of recombinant AAV vectors.

Authors:  N Zeltner; E Kohlbrenner; N Clément; T Weber; R M Linden
Journal:  Gene Ther       Date:  2010-03-25       Impact factor: 5.250

10.  Adenovirus gene transfer to amelogenesis imperfecta ameloblast-like cells.

Authors:  Anton V Borovjagin; Juan Dong; Michael J Passineau; Changchun Ren; Ejvis Lamani; Olga A Mamaeva; Hongju Wu; Enid Keyser; Miho Murakami; Shuo Chen; Mary MacDougall
Journal:  PLoS One       Date:  2011-10-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.